This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Wound Healing  • Genetics  • Genetic Disorders  • Alert me on articles by topic

Arch Dermatol. 2000;136:1259-1260.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THE current issue of the ARCHIVES, Falabella and colleagues¹ report on their expanded experience with the use of Apligraf (Organogenesis Inc, Canton, Mass), a commercially available artificial skin bioequivalent, in the treatment of acute and chronic wounds in 15 patients with inherited epidermolysis bullosa (EB). This study is a natural extension of their positive experience in the short-term treatment of an infant with a generalized form of EB simplex.² This extended report is a timely and highly anticipated one, since the EB lay organizations (Dystrophic EB Research Association) in North America and Europe, the National EB Registry, and other centers involved in EB research and treatment have received hundreds of requests for information on this potential breakthrough in the day-to-day management of this disease.

This work is a natural outgrowth of the efforts of many investigators who, beginning in the mid to late 1980s, initially attempted to cover burn . . . [Full Text of this Article]

RELATED ARTICLE

Tissue-Engineered Skin (Apligraf) in the Healing of Patients With Epidermolysis Bullosa Wounds
Anna F. Falabella, Isabel C. Valencia, William H. Eaglstein, and Lawrence A. Schachner
Arch Dermatol. 2000;136(10):1225-1230.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Longevity of a Bilayered Skin Substitute After Application to Venous Ulcers
Phillips et al.
Arch Dermatol 2002;138:1079-1081.
ABSTRACT | FULL TEXT